SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group-Reference-Cited by-同舟云学术

SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group

Published:2011-10-12 Issue:1 Volume:12 Page:
ISSN:1471-2350
Container-title:BMC Medical Genetics
language:en
Short-container-title:BMC Med Genet

Author:

Santos Paulo CJL,Soares Renata AG,Nascimento Raimundo M,Machado-Coelho George LL,Mill José G,Krieger José E,Pereira Alexandre C

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Genetics

Link

http://link.springer.com/content/pdf/10.1186/1471-2350-12-136.pdf

Reference26 articles.

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005, 366 (9493): 1267-1278.

2. Ghatak A, Faheem O, Thompson PD: The genetics of statin-induced myopathy. Atherosclerosis. 210 (2): 337-343.

3. Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol. 2006, 97 (8A): 69C-76C.

4. Armitage J: The safety of statins in clinical practice. Lancet. 2007, 370 (9601): 1781-1790. 10.1016/S0140-6736(07)60716-8.

5. Gotto AM: Statins, cardiovascular disease, and drug safety. Am J Cardiol. 2006, 97 (8A): 3C-5C.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of a patient at very high cardiovascular risk with myositis during high-intensity statin therapy;Meditsinskiy sovet = Medical Council;2024-05-19

2. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS;Polski Merkuriusz Lekarski;2023

3. Chapter 2: Pharmacogenomics: Drug Exposure and Response;Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process, 2nd Edition;2022-08

4. Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review;Pharmacogenomics and Personalized Medicine;2022-06

5. Association between single nucleotide polymorphism SLCO1B1 gene and simvastatin pleiotropic effects measured through flow-mediated dilation endothelial function parameters;Therapeutic Advances in Cardiovascular Disease;2022-01